Onyx Bridge Wealth Group’s Briacell Therapeutics BCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-333
Closed -$28.3K 295
2024
Q4
$28.3K Hold
333
﹤0.01% 282
2024
Q3
$62K Hold
333
0.01% 278
2024
Q2
$57K Hold
333
0.01% 265
2024
Q1
$109K Buy
333
+133
+67% +$73.3K 0.02% 248
2023
Q4
$176K Buy
+200
New +$144K 0.04% 233

Other funds holding BCTX

Onyx Bridge Wealth Group's BCTX Position: Q1 2025 in Review

Onyx Bridge Wealth Group sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 333 shares — an estimated $28.3K sold.

Onyx Bridge Wealth Group first reported a position in BCTX in Q4 2023 and held it in 5 quarters. The position peaked at $176K in Q4 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Onyx Bridge Wealth Group reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Onyx Bridge Wealth Group sold 333 Briacell Therapeutics shares in Q1 2025, an estimated $28.3K.
  • Onyx Bridge Wealth Group first reported a position in Briacell Therapeutics in Q4 2023 and held it in 5 quarters.
  • Onyx Bridge Wealth Group's Briacell Therapeutics position peaked at $176K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Onyx Bridge Wealth Group's 13F filing for Q1 2025, filed 29 Apr 2025.